<h4>Background</h4>Enhancer of zeste homolog 2 (EZH2) is frequently upregulated in prostate cancer (PCa) and further increased in castration-resistant prostate cancer (CRPC), a lethal state characterized by profound immune dysfunction. The gene discussed is EZH2; the disease is prostate carcinoma.